Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics confident of further growth

Its European markets were largely flat but the company still managed to achieve top-line growth of 18% on a constant currency basis
Dust mites
These were "mitey" good figures

Allergy vaccines specialist Allergy Therapeutics plc (LON:AGY) continued to gain market share in the second half of 2016.

The group issued half-year results that largely confirmed the numbers in its January trading update.

Revenue rose 39% to £40.4mln from £29.0mln in the second half of 2015, helped by favourable exchange rate movements. Stripping out currency fluctuations, the increase was still an impressive 18%.

The revenue uplift was achieved despite European markets as a whole showing no or very little growth.

Germany, Austria, Spain and The Netherlands contributed the most to top-line growth, Allergy revealed, although all markets saw sales head higher.

In the 12 months to 31 December 2016, market share grew to 13% compared to 12% in the year ended 30 June 2016 in the markets in which the group competes.

The flagship pollen allergy Pollinex franchise continues to expand, while Acarovac Plus, its dust mite allergy treatment, continues to grow well in Spain and has been launched in Austria.

Sales of synbiotics products – products that are a synthesis of prebiotics (substances that encourage the growth of microorganisms) and probiotics (health-giving microorganisms) - have performed well in Italy and Spain.

Profit before tax shot up to £7.2mln from £1.3mln as research & development (R&D) costs declined to £3.82mln from £6.54mln the previous year.

“The board and management team expect that growth in net sales will continue in the second half of the year and have great confidence in the future of the business,” the company said.

“As planned, research and development costs are expected to rise significantly in the second half of the year compared to the first half, reflecting the exciting preparation for the expected start of two major trials (US Grass MATA MPL Phase II and PQ Birch Phase III) as well as investment in infrastructure to progress the important TAV process. Other costs are expected to be similar to H1 2017,” Allergy Therapeutics confirmed.

Broker finnCap, which rates the shares a 'buy' said that apart from a slightly lower than expected first half R&D charge, “which is likely to be timing related”, it will make no change to its full-year forecasts.

“We retain a near term target price of 43p and point to the further upside that Pollinex Quattro (PQ) Grass programme in the US offers investors,” the broker said.

Shares in Allergy rose 2.1% to 24.5p on the results.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
blood cells
October 23 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use